Summary of Mouse Experiments
| Treatment | Cells injected | Cures (n) |
|---|---|---|
| Group 1 | 1 × 106 | 0/5 |
| Untreated | ||
| 213Bi-rituximab, 925 kBq (day 7) | 1 × 106 | 0/5 |
| 213Bi-rituximab, 3,700 kBq (day 7) | 1 × 106 | 0/5 |
| 213Bi, free, 1,295 kBq (day 7) | 1 × 106 | 0/5 |
| 213Bi-HER2/neu, 1,295 kBq (day 7) | 1 × 106 | 0/5 |
| 10 μg of rituximab (day7) | 1 × 106 | 0/5 |
| Group 2 | 5 × 105 | 0/6 |
| Untreated | ||
| 213Bi-rituximab, 2,775 kBq (day 7) | 5 × 105 | 2/6 |
| 213Bi-rituximab, 2,775 kBq (days 7, 13) | 5 × 105 | 3/7 |
| 10 μg of rituximab (days 7, 13) | 5 × 105 | 1/4 |
| 213Bi-HER2/neu, 2,775 kBq (day 7) | 5 × 105 | 0/5 |
| Group 3 | 1 × 106 | 0/6 |
| Untreated | ||
| 213Bi-rituximab, 2,775 kBq (day 7) | 1 × 106 | 0/6 |
| 213Bi-rituximab, 2,775 kBq (days 7, 12) | 1 × 106 | 0/6 |
| 213Bi-rituximab, 2,775 kBq (days 7, 12, 19) | 1 × 106 | 0/6 |
| Group 4 | 1 × 106 | 0/8 |
| Untreated | ||
| 213Bi-rituximab, 3,700 kBq (day 4) | 1 × 106 | 6/8 |
| 131I-tositumomab, 2,035 kBq (day 4) | 1 × 106 | 6/8 |
| 90Y-rituximab, 925 kBq (day 4) | 1 × 106 | 0/8 |
| 10 μg of rituximab (day 4) | 1 × 106 | 1/8 |